Center for Advanced Therapeutics
The Center for Advanced Therapeutics is designed to advance the discovery and development of new medicines arising from basic biomedical research at The Wistar Institute. The Center convenes a multi-disciplinary team of biologists, chemists, clinicians, and business development collaborators to identify impactful new discoveries that have the potential for development into clinically relevant technologies and therapeutics that can improve patient care and enhance human health.
The Center will advance the drug discovery breakthroughs of Wistar scientists utilizing biology, chemistry and artificial intelligence (AI) to capitalize on new areas of investigation and expand vital collaborations across public-private sectors, integrating perspectives, expertise and technology to reduce the burden of human disease.
Welcome to the Center for Advanced Therapeutics. This groundbreaking new collaborative laboratory space is intended to marry research from some of the brightest Wistar scientists with the power of industry collaborators to help translate those discoveries into real-world therapies.
The Center for Advanced Therapeutics will focus on:
- Bridging biology and chemistry expertise through recruitment of computational chemists to design new chemical entities that advance Wistar technologies towards clinical assets;
- Applying artificial intelligence and machine learning tools to accelerate the challenging process of drug discovery and development;
- Uniting multidisciplinary expertise and industry collaborations to turn early-stage discoveries into future medicine; and
- Expanding the study of immunity and autoimmune diseases, areas that complement Wistar cancer biology and viral disease knowledge.
We’re committed to fostering an atmosphere where scientists, clinicians, industry leaders, and other collaborators join together to exchange ideas, challenge assumptions, and inspire one another to advance drug discovery breakthroughs.
Philadelphia Drug Discovery Forum
The mission of the Philadelphia Drug Discovery Forum is to bring together drug discovery scientists from academia, industry and government to present and discuss their non-proprietary research.
Learn more here.
Leadership and Members
Paul M. Lieberman, Ph.D.
- Hilary Koprowski, M.D., Endowed Professor
- Program Leader, Genome Regulation and Cell Signaling Program, Ellen and Ronald Caplan Cancer Center
- Director, Center for Chemical Biology & Translational Medicine
Focus: Epstein-Barr virus (EBV); viruses that cause cancer; autoimmune diseases; small molecules
Troy Messick, Ph.D.
Research Associate Professor
Focus: advancing small molecule programs from preclinical research through clinical trials
Samantha Soldan, Ph.D.
Senior Staff Scientist
Focus: preclinical multiple sclerosis research and autoimmune diseases
Jayaraju Dheekollu, Ph.D.
Staff Scientist
Joseph Salvino, Ph.D.
Professor
Virology Focus: HIV, EBV, SARS-Co-V2, anti-viral drug discovery, chemical-biology tools to probe viral mechanisms
Heather A. Steinman, Ph.D., MBA
Senior Vice President for Business Development
Executive Director, Technology Transfer
Luis Montaner, D.V.M., D.Phil.
Executive Vice President
Director, HIV Cure and Viral DIseases Center
Herbert Kean, M.D., Family Professor
Jessie Villanueva, Ph.D.
Associate Professor
David Weiner, Ph.D.
Executive Vice President
Director, Vaccine & Immunotherapy Center
Ian Tietjen, Ph.D.
Education Director of Global Studies
Assistant Professor
Joel Cassel
Managing Director
Molecular Screening and Protein Expression Facility